89bio, Inc.
ETNB
$14.74
-$0.13-0.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.53% | 7.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 52.58% | -37.78% | |||
| Operating Income | -52.58% | 37.78% | |||
| Income Before Tax | -55.68% | 39.76% | |||
| Income Tax Expenses | 449.64% | -46.69% | |||
| Earnings from Continuing Operations | -56.44% | 39.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -56.44% | 39.78% | |||
| EBIT | -52.58% | 37.78% | |||
| EBITDA | -52.59% | 37.79% | |||
| EPS Basic | -45.03% | 52.29% | |||
| Normalized Basic EPS | -40.56% | 51.85% | |||
| EPS Diluted | -45.03% | 52.29% | |||
| Normalized Diluted EPS | -40.56% | 51.85% | |||
| Average Basic Shares Outstanding | 7.87% | 26.22% | |||
| Average Diluted Shares Outstanding | 7.87% | 26.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||